George Richenberg PhD thesis - Supplementary table 6.11: Summary statistics for sfFDR-identified novel genome-wide significant (FP<5x10-8), independent lead variants associated with overall (inc), overall (exc), DNMT3A-, TET2- and ASXL1-mutant CH compared with acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) and myeloid leukaemia (ML) in FinnGen

Summary statistics for novel, genome-wide significant (FP< 5×10⁻⁸), independent lead variants associated with CH risk identified using the sfFDR method in individuals of European ancestry (25,657 cases and 342,869 controls). These variants are compared with GWAS summary statistics of acute myeloid leukaemia (AML) (322 cases; 378,747 controls), myelodysplastic syndrome (MDS) (979 cases; 378,296 controls), myeloproliferative neoplasm (MPN) (2,791 cases; 497,256 controls) and myeloid leukaemia (ML) (855 cases; 378,749 controls) in individuals of European ancestry from FinnGen.